Bourgonje, Arno Rolf

Dijkstra, Gerard

Faber, Klaas Nico

Gabriëls, Ruben Yannick

von Martels, Julius Zweder Hubertus

English

The invention relates generally to biomarkers, methods and kits to predict therapy response in patients, in particular in patients having inflammatory bowel disease (IBD). Provided is a method for predicting whether a human subject is likely to show a clinical response to therapy with an antibody or pharmacological antagonist that targets α4β7 integrin, preferably vedolizumab induction therapy, comprising (i) determining the level of eotaxin-1 in a sample obtained from the subject, and; (ii) classifying the subject as a responder based on the leve of eotaxin-1

Dissertations of the University of Groningen

   University of GroningenBiomarker, kit and method for predicting clinical responsiveness to therapy with an agent thattargets alpha4beta7 integrinDijkstra, Gerard; Faber, Klaas Nico; Bourgonje, Arno Rolf; Gabriëls, Ruben Yannick; vonMartels, Julius Zweder HubertusIMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.Document VersionPublisher's PDF, also known as Version of recordPublication date:2020Link to publication in University of Groningen/UMCG research databaseCitation for published version (APA):Dijkstra, G., Faber, K. N., Bourgonje, A. R., Gabriëls, R. Y., & von Martels, J. Z. H. (2020). Biomarker, kitand method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7integrin. (Patent No. WO2020226498).CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license.More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.Download date: 28-12-2022

Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha<sub>4</sub>beta<sub>7</sub> integrin

https://pure.rug.nl/ws/files/150131261/WO2020226498A1.pdf

Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha<sub>4</sub>beta<sub>7</sub> integrin

Abstract

Similar works

Full text

Available Versions

Dissertations of the University of Groningen